Serotransferrin downregulation linked to coronary artery disease progression and inversely correlates with troponin I
Background
Coronary artery disease (CAD) is a prevalent cardiovascular condition driven by atherosclerosis and plaque accumulation, necessitating a deeper understanding of its inflammatory mechanisms. Despite its high prevalence, the specific proteins involved in CAD pathogenesis, especially those related to iron metabolism, remain underexplored. Given the increased incidence of iron deficiency in CAD patients, identifying iron-associated proteins could reveal critical insights into disease progression and potential therapeutic targets, addressing a key gap in current diagnostic and treatment strategies.
Study Design
Researchers utilized isobaric tags for relative and absolute quantification (iTRAQ) to generate a differential protein profile from the plasma of CAD patients compared to healthy controls. Protein selection focused on peptide similarity and specific fold change criteria, with an emphasis on identifying iron transporter proteins. The expression levels of these selected proteins were subsequently validated using Western blotting and enzyme-linked immunosorbent assay (ELISA) to confirm the iTRAQ findings.
Results
Analysis revealed a total of 197 differentially expressed proteins (DEPs) in CAD patient plasma. Notably, serotransferrin (TF), a crucial iron transporter, showed significant downregulation in samples from CAD patients compared to healthy controls. The cardiac marker troponin I (cTnI) demonstrated a clear inverse relationship with TF levels, suggesting a potential link between TF and cardiac injury severity. Further investigation indicated that the decreased availability of TF might be attributed to its phosphorylation by calcium/calmodulin-dependent protein kinase (CaMKK2). In silico analyses using Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG), and Cytoscape confirmed that TF's role in CAD is currently underexplored. > Serotransferrin protein was significantly associated with CAD progression and inversely correlated with cTnI, highlighting its potential as a novel biomarker.
Why It Matters
Identifying serotransferrin (TF) as a downregulated protein in CAD and its inverse correlation with cTnI opens new avenues for diagnostic and therapeutic development. For clinicians, TF could serve as a novel biomarker for CAD progression, potentially improving risk stratification beyond existing markers. For researchers, understanding TF's phosphorylation by CaMKK2 provides a specific mechanistic target for drug development. While still in the preclinical stage, this finding suggests that modulating TF levels or its phosphorylation pathway could offer a future strategy to intervene in CAD, moving beyond current standard-of-care limitations.